At the Shanghai New Coronary Pneumonia Epidemic Prevention and Control Press Conference on March 16, Zhang Quan, Director of the Shanghai Science and Technology Commission, introduced positive progress in the development of new antibody drugs; through screening of 1.78 million samples, A batch of active compounds was obtained.
That, in addition, to promote the deployment of multi-route vaccine research and development have made good progress, mRNA vaccine field, animal toxicology, and efficacy have started pre-primate experiments, clinical trials are expected in mid-April; virus-like particle (VLP) In the field of vaccines, mouse immune experiments have produced specific antibodies.
Zhang Quan said that the next step is for the Municipal Science and Technology Commission to “focus on the current”, further strengthen collaborative research, and accelerate the development of key tasks such as drugs and vaccines. Build capacity, improve the scientific and technological collaborative research system for major and emerging epidemic diseases and focus on improving prevention and response capabilities.